XML 59 R34.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Acquisition of Assets (Details Textual) (USD $) | 0 Months Ended | 1 Months Ended
--- | --- | ---
Nov. 06, 2014 | Jan. 30, 2013
Business Acquisition, Cost of Acquired Entity, Cash Paid |  | $ 400,000 us-gaap_PaymentsToAcquireBusinessesGross
Business Acquisition Purchases Price Allocation Assets Acquired |  | 100,000 antb_BusinessAcquisitionPurchasesPriceAllocationAssetsAcquired
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset | 55,000 us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 |
Licensee |  |
Cumulative Sales Amount |  | 500,000,000 antb_CumulativeSalesAmount / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = antb_LicenseeMember
Maximum |  |
Business Acquisition Contingent Consideration At Fair Values |  | 44,000,000 antb_BusinessAcquisitionContingentConsiderationAtFairValues / us-gaap_RangeAxis = us-gaap_MaximumMember
Business Combination, Contingent Consideration, Liability, Current |  | 44,000,000 us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent / us-gaap_RangeAxis = us-gaap_MaximumMember
Exclusive License Of Multi Day Injectable Insulin In Us |  |
Business Acquisition Contingent Consideration At Fair Values |  | 2,000,000 antb_BusinessAcquisitionContingentConsiderationAtFairValues / us-gaap_ContingentConsiderationByTypeAxis = antb_ExclusiveLicenseOfMultiDayInjectableInsulinInUsMember
Business Acquisition Contingent Consideration Amount Payment Period |  | 30 days
Business Combination, Contingent Consideration Arrangements, Description |  | Two million dollars ($2,000,000) to be paid within 30 days after the exclusive license of the multi-day injectable insulin in the United States to a commercial pharmaceutical company.
Phase Two B Clinical Studies For Multi Day Injectable Insulin |  |
Business Acquisition Contingent Consideration At Fair Values |  | 2,000,000 antb_BusinessAcquisitionContingentConsiderationAtFairValues / us-gaap_ContingentConsiderationByTypeAxis = antb_PhaseTwoBClinicalStudiesForMultiDayInjectableInsulinMember
Business Acquisition Contingent Consideration Amount Payment Period |  | 30 days
Business Combination, Contingent Consideration Arrangements, Description |  | Two million dollars ($2,000,000) related to the initiation of Phase 2b clinical studies for a multi-day injectable insulin, payable 30 days after the first dosing of a patient in a formal Phase 2b clinical study;
Phase Three B Clinical Studies For Multi Day Injectable Insulin |  |
Business Acquisition Contingent Consideration At Fair Values |  | 5,000,000 antb_BusinessAcquisitionContingentConsiderationAtFairValues / us-gaap_ContingentConsiderationByTypeAxis = antb_PhaseThreeClinicalStudiesForMultiDayInjectableInsulinMember
Business Acquisition Contingent Consideration Amount Payment Period |  | 30 days
Business Combination, Contingent Consideration Arrangements, Description |  | Five million dollars ($5,000,000) after the initiation of Phase 3 clinical studies for the multi-day injectable insulin by the Company or a licensee of the Company, payable 30 days after the first dosing of a patient in a formal Phase 3 clinical study.
Approval By Fda Or Emea To Allow Marketing and Sales Of Multi Day Injectable Insulin |  |
Business Acquisition Contingent Consideration At Fair Values |  | 10,000,000 antb_BusinessAcquisitionContingentConsiderationAtFairValues / us-gaap_ContingentConsiderationByTypeAxis = antb_ApprovalByFdaOrEmeaToAllowMarketingAndSalesOfMultiDayInjectableInsulinMember
Business Acquisition Contingent Consideration Amount Payment Period |  | 30 days
Business Combination, Contingent Consideration Arrangements, Description |  | Ten million dollars ($10,000,000) upon the approval by the FDA or EMEA to allow the marketing and sales of the multi-day injectable insulin by the Company or a licensee of the Company, payable 30 days after the receipt of the approval letter or notice from the FDA or EMEA.
Twelve Month Cumulative Sales Of Multi Day Injectable Insulin |  |
Business Acquisition Contingent Consideration At Fair Values |  | $ 25,000,000 antb_BusinessAcquisitionContingentConsiderationAtFairValues / us-gaap_ContingentConsiderationByTypeAxis = antb_TwelveMonthCumulativeSalesOfMultiDayInjectableInsulinMember
Business Acquisition Contingent Consideration Amount Payment Period |  | 90 days
Business Combination, Contingent Consideration Arrangements, Description |  | Twenty five million dollars ($25,000,000) if the twelve month cumulative sales of the multi-day injectable insulin by the Company or a licensee of the Company reaches five hundred million dollars ($500,000,000) in any one given twelve consecutive month period, so long as such period occurs during the life of the patents included in the purchased assets, payable 90 days after the twelfth month in which sales equaled or exceeded five hundred million dollars.

X
- Definition Business acquisition contingent consideration amount payment period. + References No definition available. + Details
Name: | antb_BusinessAcquisitionContingentConsiderationAmountPaymentPeriod
Namespace Prefix: | antb_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business acquisition contingent consideration at fair value. + References No definition available. + Details
Name: | antb_BusinessAcquisitionContingentConsiderationAtFairValues
Namespace Prefix: | antb_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition purchase price allocation assets acquired. + References No definition available. + Details
Name: | antb_BusinessAcquisitionPurchasesPriceAllocationAssetsAcquired
Namespace Prefix: | antb_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cumulative sales amount. + References No definition available. + Details
Name: | antb_CumulativeSalesAmount
Namespace Prefix: | antb_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of right to a contingent consideration asset. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=antb_ApprovalByFdaOrEmeaToAllowMarketingAndSalesOfMultiDayInjectableInsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=antb_ExclusiveLicenseOfMultiDayInjectableInsulinInUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=antb_PhaseThreeClinicalStudiesForMultiDayInjectableInsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=antb_PhaseTwoBClinicalStudiesForMultiDayInjectableInsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=antb_TwelveMonthCumulativeSalesOfMultiDayInjectableInsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=antb_LicenseeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |